|Other Names||BRCA2 and CDKN1A-interacting protein, P21- and CDK-associated protein 1, Protein TOK-1, BCCIP, TOK1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1923b was selected from the C-term region of human BCCIP. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||May promote cell cycle arrest by enhancing the inhibition of CDK2 activity by CDKN1A. May be required for repair of DNA damage by homologous recombination in conjunction with BRCA2. May not be involved in non-homologous end joining (NHEJ).|
|Cellular Location||Nucleus Note=Colocalizes with BRCA2 in discrete nuclear foci|
|Tissue Location||Expressed at high levels in testis and skeletal muscle and at lower levels in brain, heart, kidney, liver, lung, ovary, pancreas, placenta, and spleen|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
BCCIP was isolated on the basis of its interaction with BRCA2 and p21 proteins. It is an evolutionarily conserved nuclear protein with multiple interacting domains. The N-terminal half shares moderate homology with regions of calmodulin and M-calpain, suggesting that it may also bind calcium. Functional studies indicate that this protein may be an important cofactor for BRCA2 in tumor suppression, and a modulator of CDK2 kinase activity via p21.
Lu, H., et al., Mol. Cell. Biol. 25(5):1949-1957 (2005).Meng, X., et al., Cell Cycle 3(3):343-348 (2004).Robson, M., et al., J. Med. Genet. 39(2):126-128 (2002).Armakolas, A., et al., Hum. Mutat. 19(1):81-82 (2002).Liu, J., et al., Oncogene 20(3):336-345 (2001).
If you have any additional inquiries please email technical services at email@example.com.